

G¹

corresponds to a peptide or a polypeptide, capable of circulating in the body.

On page 8, replace the fourth full paragraph spanning lines 22-33 with the one submitted herein.

G²

Other monoclonal antibodies according to the invention can also be prepared against a peptide comprised in the extracellular domain of the receptor as described in figure 2 SEQ ID NO: 2. An advantageous peptide corresponds for instance to the amino acid sequence comprised between amino acid 1 and amino acid 229 of SEQ ID NO: 2. According to another embodiment of the invention, the antibodies can be prepared against a polypeptide modified by substitution of one or more amino acids, provided that antibodies directed against the non modified extracellular domain of the IFN-R, recognize the modified polypeptide or peptide.

On page 10, replace the third full paragraph spanning lines 11-16 with the one submitted herein.

G³

One particular antibody satisfying the requirements of the invention, is such as it directed against an epitope on the amino acid sequence comprised between amino acid 27 and amino acid 427 of the extracellular domain of the human IFN-R as represented on figure 2 SEQ ID NO: 2.

On page 14, replace the first full paragraph spanning lines 4-13 with the one submitted herein.

G⁴

A fragment of DNA containing the sequence coding for the extracellular domain (amino acids 27 to 427) of the human INF-R (figure 2 SEQ ID NO: 2), in which an extra-sequence coding for 5 histidyl residues was introduced just before the termination codon, was cloned in the expression vectors